OncoCyte Corporation announced that Dr. Jennifer Levin Carter and Mr. John Peter Gutfreund are not standing for re-election at its upcoming Annual Meeting of Shareholders to be held on June 23, 2023. Jennifer Levin Carter, 59, joined the company's Board of Directors in August 2020 and is not standing for re-election. Dr. Carter is a healthcare executive, investor, board member and entrepreneur with a track record of developing and investing in innovative strategies and solutions at the intersection of and healthcare IT and services, digital health and machine learning, precision medicine, and genomics.

Dr. Carter has been a Managing Director at Sandbox Industries and Blue Venture Fund since March 2021. Previously, Dr. Carter served as Managing Director of JLC Precision Health Strategies from July 2020 to April 2021 and VP and Head of Precision Health at Integral Health (now Valo Health), from March 2019 to August 2020. In 2018, Dr. Carter founded TrialzOWN Inc. Prior to serving as CEO of TrialzOWN, Dr. Carter founded N-of-One Inc. and served as its Chief Executive Officer from 2008 to 2012, and as its Chief Medical Officer from 2012 until its acquisition by Qiagen in 2019.

Prior to founding N-of-One, Dr. Carter spent nine years working as an Investment Consultant with Levin Capital Strategies and with other groups specializing in biotechnology and life sciences investments evaluating existing and emerging markets, new medical technologies, and early-stage companies. After obtaining her medical degree, Dr. Carter practiced internal medicine at Mount Auburn Hospital in Cambridge, MA. Dr. Carter serves on the board of directors of CareMax Inc. Dr. Carter received a BS degree from Yale University, an MD from Harvard Medical School, an MPH from the Harvard School of Public Health, and an MBA from MIT.

John Peter Gutfreund, 37, joined the company's Board of Directors in July 2022 and is not standing for re-election. Since October 2019, Mr. Gutfreund has served as Managing Partner of Halle Capital Management. Mr. Gutfreund serves on the board of several Halle portfolio companies.

Mr. Gutfreund is a trustee at Montefiore Health System, where he serves as a member of the investment committee. Prior to joining Halle Capital Management, Mr. Gutfreund was the Director of Research at Glenview Capital Management from March 2013 to September 2019. Mr. Gutfreund worked in the Investment Banking industry earlier in his career and holds a BA from New York University.